Compare
Galectin Therapeutics Inc vs Marker Therapeutics, Inc. vs Genelux Corp vs Evofem Biosciences, Inc.
| Latest fiscal year | Galectin Therapeutics Inc GALT | Marker Therapeutics, Inc. MRKR | Genelux Corp GNLX | Evofem Biosciences, Inc. EVFM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $3.55M | $8.0K | $20.18M |
| Revenue growth (YoY) | n/a | -46.2% | 0.0% | +4.2% |
| Gross margin | n/a | n/a | n/a | 77.1% (computed) |
| Operating margin | n/a | -363.5% | n/m | 16.7% |
| Net margin | n/a | -343.0% | n/m | 1.9% |
| Net income | -$30.84M | -$12.16M | -$32.15M | $391.0K |
| EPS (Diluted) | -$0.48 | -$0.79 | -$0.86 | $0.00 |
| Operating cash flow | -$23.88M | -$12.01M | -$25.27M | -$1.99M |
| Free cash flow | n/a | n/a | -$26.37M | -$2.00M |
| Cash & equivalents | $17.72M | $16.07M | $5.33M | $578.0K |
| Total assets | $19.53M | $19.07M | $19.03M | $20.27M |
| Total liabilities | $145.73M | $2.27M | $7.48M | $89.71M |
| Shareholders' equity | -$127.92M | $16.80M | $11.54M | -$74.34M |
| Return on year-end equity | n/a | -72.4% | -278.5% | n/a |
| Shares outstanding | 65.20M | 16.70M | 38.14M | 126.69M |
Revenue, most recent five fiscal years
| Fiscal year | Galectin Therapeutics Inc | Marker Therapeutics, Inc. | Genelux Corp | Evofem Biosciences, Inc. |
|---|---|---|---|---|
| Latest | n/a | $3.55M Ended 2025-12-31 | $8.0K Ended 2025-12-31 | $20.18M Ended 2025-12-31 |
| 1 year earlier | n/a | $6.59M Ended 2024-12-31 | $8.0K Ended 2024-12-31 | $19.36M Ended 2024-12-31 |
| 2 years earlier | n/a | $3.31M Ended 2023-12-31 | $170.0K Ended 2023-12-31 | $18.22M Ended 2023-12-31 |
| 3 years earlier | n/a | $3.51M Ended 2022-12-31 | $11.07M Ended 2022-12-31 | $16.84M Ended 2022-12-31 |
| 4 years earlier | n/a | $1.24M Ended 2021-12-31 | n/a | $8.24M Ended 2021-12-31 |